Table 9.
Recent marine anticancer drugs allowed by the EMA and/or the FDA
| Generic name | Brand name | Source | Chemical class | Clinical use | CAS No | Marketing authorization date |
|---|---|---|---|---|---|---|
| Lurbinectedin | Zepzelca | Tunicate | Alkaloid | Ovarian cancer | 497871-47-3 | 2020 FDA |
| Polatuzumab vedotin | Polivy | Mollusk/cyanobacterium | Antibody drug conjugate | Breast cancer | 1313206-42-6 |
2019 FDA 2020 EMA |
| Enfortumab vedotin | Padcev | Mollusk/cyanobacterium | Antibody drug conjugate | Urothelial cancer | 1346452-25-2 |
2019 FDA 2021 EMA |
| Belantamab mafodotin | Blenrep | Mollusk/cyanobacterium | Antibody drug conjugate | Multiple myeloma | 2050232-20-5 |
2020 FDA 2020 EMA |